Infliximab as first-line therapy for Crohn's disease is premature.
Greenberg
Gordon R
GR
Department of Medicine, Mt Sinai Hospital, University of Toronto, Ontario, Canada. ggreenberg@mtsinai.on.ca
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab